Deep Tech Startups

Aperiam Bio uses computer-vision algorithms to identify "hyperfolding" protein variants with improved expression, solubility, and stability, aiming for order-of-magnitude gains in protein performance. It applies this technology to develop technical reagents, shelf-stable enzymes for cosmetics, and pulmonary biologic therapeutics for its partners.

2 investors

Apix Analytics builds compact, field-ready gas analysis instruments that deliver real-time measurement for applications such as natural gas, biomethane, hydrogen, and pollutant analysis. Founded from a collaboration between CEA-LETI and Caltech, it serves energy and industrial customers through a global network of integrators and distributors.

2 investors

Apoha develops a molecular science data class used to design medicines, food, and materials. It operates in the deeptech and biotech space focused on molecular data for R&D applications.

2 investors

Apolink provides on-demand satellite communications infrastructure, enabling real-time telemetry and command links for space operators managing satellites for applications including disaster response, wildfire detection, and intelligence gathering.

2 investors

Aquagga develops field-deployable technology that uses a patented hydrothermal process to permanently destroy PFAS chemicals, breaking them down into harmless byproducts. It serves industries, municipalities, and government agencies seeking to address PFAS water contamination.

2 investors

AQuark Technologies develops miniaturised quantum hardware based on cold-atom sensing and timing technologies, using expertise in vacuum engineering, micro-fabrication, and photonics. Its compact, energy-efficient quantum devices target applications in navigation, communication, security, medical diagnostics, and resource exploration outside controlled lab settings.

2 investors

AquiSense develops UV-C LED water disinfection systems that treat water without chemicals, serving homes, factories, restaurants, remote communities, and space applications. It also makes UV-C LED products for laboratory research and for air and surface disinfection.

2 investors

Architect Therapeutics is a drug discovery company that uses C-H bond activation chemistry to synthesize novel 3D small-molecule scaffolds and screen them against difficult-to-drug targets. It develops oral therapies with an emphasis on immunology and oncology.

2 investors

Archon Biosciences develops a computational protein design platform leveraging AI and deep learning for therapeutic and vaccine applications. The company was founded in 2023 by James Lazarovits and George Ueda, Ph.D., building on research in AI-driven protein engineering and nanomaterial delivery.

2 investors

Arcoscan develops biometric and AI-based age verification technology, built in collaboration with SRI International, that identifies a user's age through a face scan rather than physical IDs. Its technology targets age-restricted industries such as alcohol, tobacco, cannabis, online gambling, crypto, and gaming through mobile apps, point-of-sale, and embedded device integrations.

2 investors

Arcturus builds tools for producing 3D and volumetric video from live action, including interactive highlights, replays, and analysis for sports and broadcast. Its technology reconstructs a digital twin of on-field action and outputs to standard 2D broadcast, stereoscopic VR, and lightfield displays.

2 investors

Aren offers a patented software toolset that uses computer vision and machine learning to detect, quantify, and track damage on civil infrastructure assets such as bridges, producing 3D digital twins and predictive maintenance and capital allocation plans. It serves civil engineers and infrastructure asset owners to de-risk asset management, prioritize repairs, and optimize infrastructure spending.

2 investors

Arena AI develops an electromagnetic and RF-focused AI platform, including a product called Atlas RF Studio. It offers a platform, services, and research aimed at applying artificial intelligence to electromagnetic and radio frequency domains.

2 investors

Arena Physica builds Atlas, an AI agent platform for hardware engineering that pairs general intelligence with deterministic physics models and integrations to design, simulation, and test tools. It helps engineering teams debug system failures, validate board designs, and optimize closed-loop hardware systems.

2 investors

ArgusEye builds autonomous AI engineers for product security in cyber-physical systems, operating inside R&D and engineering teams to model threats, prescribe security controls, and generate audit-ready evidence. The platform targets regulated industries including medical devices, consumer IoT, aerospace, robotics, industrial automation, and defense.

2 investors

ARIZ Precision Medicine develops cancer treatments that combine biological and nanotechnology approaches to target the genetic and epigenetic drivers of cancer, aiming to kill cancer cells while leaving healthy cells undamaged. The company designs targeted drug delivery systems intended to concentrate drugs inside cancer cells.

2 investors

Arnatar develops RNA therapeutics using its DARGER platform, which combines gene silencing via siRNA with protein upregulation through antisense oligonucleotides (ACT-UP1). The company targets cardiovascular, metabolic, CNS, and rare diseases.

2 investors

Arontier is a company that applies artificial intelligence to drug discovery, using proprietary technology and data to develop treatments for incurable and rare diseases. Founded in 2017, it collaborates with companies, experts, and scholars on new medicines and genetic editing.

2 investors

Artica Therapeutics develops orally bioavailable small molecule inhibitors that use covalent chemistry to achieve antibody-like efficacy, positioned as an "antibody-in-a-pill" approach. The company targets severe autoimmune and inflammatory disorders for patients with immune-mediated conditions.

2 investors

Arx develops secure chips that embed blockchain authentication into physical items like apparel, collectibles, and certificates, enabling decentralized provenance verification and digital experiences without centralized servers.

2 investors

AscendArc builds low-cost, high-bandwidth small geostationary (GEO) satellites using volume-production methods adapted from LEO manufacturing, aimed at rapid deployment and lower-cost satellite communications. It targets commercial and military connectivity applications.

2 investors

Ascendance develops hybrid-electric propulsion systems for next-generation aircraft and unmanned aerial vehicles, serving civil and defence operators seeking improved range, efficiency, and reduced environmental impact. The company's technology combines thermal and electric power to enable aircraft with significantly greater endurance and faster turnaround times than conventional alternatives.

2 investors

Ascension develops technology related to the extraction or supply of critical materials used in applications such as magnets for wind turbines, solar panel coatings, speakers, displays, and batteries. These materials support renewable energy and electronics manufacturing.

2 investors

AskBio is a gene therapy company developing adeno-associated virus (AAV)-based genetic medicines for rare and other diseases, with clinical programs such as AB-1009 for late-onset Pompe disease. It operates as a wholly owned, independent subsidiary of Bayer AG.

2 investors